All In Biotech

Free tool

FAERS Monitor: Bosulif

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217729 or its brand name (Bosulif, Bosutinib Monohydrate). Reports on generic versions are filed under their own applications.

Reports

8,981

Serious

5,051

56% of reports

Hospitalization

1,932

Death reported

799

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea2,078
  • nausea1,020
  • fatigue728
  • vomiting544
  • death538
  • rash492
  • pleural effusion458
  • neoplasm progression373
  • dyspnoea364
  • headache339
  • off label use330
  • drug intolerance318
  • malaise298
  • drug ineffective280
  • abdominal pain267

Reports by year received

View as table
YearReports
20093
20107
20117
201260
2013270
2014398
2015540
2016504
2017575
2018697
2019966
2020865
2021817
2022851
2023993
2024737
2025484
2026207

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,178 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neoplasm progressionSignal37325.423.08,636
pleural effusionSignal45817.816.27,189
drug intoleranceSignal3187.76.91,859
diarrhoeaSignal2,0787.67.312,158
nauseaSignal1,0203.02.91,429
vomitingSignal5442.72.5599
abdominal painSignal2672.72.4285
rashSignal4922.62.4512
fatigueSignal7282.22.0488
malaise2981.61.466
dyspnoea3641.51.463
death5381.51.382
headache3391.31.119
off label use3300.90.85
drug ineffective2800.50.4151

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.